1. Home
  2. IPCX vs ARCT Comparison

IPCX vs ARCT Comparison

Compare IPCX & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IPCX
  • ARCT
  • Stock Information
  • Founded
  • IPCX 2024
  • ARCT 2013
  • Country
  • IPCX United States
  • ARCT United States
  • Employees
  • IPCX N/A
  • ARCT N/A
  • Industry
  • IPCX
  • ARCT Biotechnology: Pharmaceutical Preparations
  • Sector
  • IPCX
  • ARCT Health Care
  • Exchange
  • IPCX NYSE
  • ARCT Nasdaq
  • Market Cap
  • IPCX 348.5M
  • ARCT 298.3M
  • IPO Year
  • IPCX 2025
  • ARCT N/A
  • Fundamental
  • Price
  • IPCX $10.20
  • ARCT $14.67
  • Analyst Decision
  • IPCX
  • ARCT Strong Buy
  • Analyst Count
  • IPCX 0
  • ARCT 8
  • Target Price
  • IPCX N/A
  • ARCT $52.83
  • AVG Volume (30 Days)
  • IPCX 51.5K
  • ARCT 477.9K
  • Earning Date
  • IPCX 01-01-0001
  • ARCT 08-04-2025
  • Dividend Yield
  • IPCX N/A
  • ARCT N/A
  • EPS Growth
  • IPCX N/A
  • ARCT N/A
  • EPS
  • IPCX N/A
  • ARCT N/A
  • Revenue
  • IPCX N/A
  • ARCT $143,680,000.00
  • Revenue This Year
  • IPCX N/A
  • ARCT N/A
  • Revenue Next Year
  • IPCX N/A
  • ARCT $34.79
  • P/E Ratio
  • IPCX N/A
  • ARCT N/A
  • Revenue Growth
  • IPCX N/A
  • ARCT 15.38
  • 52 Week Low
  • IPCX $10.07
  • ARCT $8.04
  • 52 Week High
  • IPCX $11.06
  • ARCT $25.88
  • Technical
  • Relative Strength Index (RSI)
  • IPCX N/A
  • ARCT 63.28
  • Support Level
  • IPCX N/A
  • ARCT $13.10
  • Resistance Level
  • IPCX N/A
  • ARCT $14.09
  • Average True Range (ATR)
  • IPCX 0.00
  • ARCT 0.96
  • MACD
  • IPCX 0.00
  • ARCT 0.09
  • Stochastic Oscillator
  • IPCX 0.00
  • ARCT 97.14

About IPCX INFLECTION POINT ACQUISITION CORP

Inflection Point Acquisition Corp III is a special-purpose acquisition company.

About ARCT Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.

Share on Social Networks: